Catalyst
Slingshot members are tracking this event:
Biogen (BIIB) Announces Phase 3 ENDEAR Results Evaluating Spinraza in Infants with Spinal Muscular Atrophy (SMA) at the British Pediatric Neurology Association Annual Conference
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BIIB |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 13, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Endear, Spinraza, Infants, Spinal Muscular Atrophy, Sma
